natgillin/translations-raw huggingface dataset:
The Agency's Committee for Medicinal Products for Human Use (CHMP) concluded that, in accordance with EU requirements, Yargesa has been shown to have comparable quality and to be bioequivalent to Zavesca.
Odbor za zdravila za uporabo v humani medicini (CHMP) pri agenciji je zaključil, da je bilo v skladu z zahtevami EU dokazano, da ima zdravilo Yargesa primerljivo raven kakovosti kot zdravilo Zavesca ter da mu je biološko enakovredno.
Yargesa is used in patients who cannot receive enzyme-replacement therapy.
Zdravilo Yargesa se uporablja pri bolnikih, ki ne morejo prejemati encimskega nadomestnega zdravljenja.
Because Yargesa is a generic medicine and is bioequivalent to the reference medicine, its benefits and risks are taken as being the same as the reference medicine's.
Ker je zdravilo Yargesa generično zdravilo in je biološko enakovredno referenčnemu zdravilu, so koristi in tveganja enaki kot pri referenčnem zdravilu.
Yargesa is a ‘generic medicine'.
Zdravilo Yargesa je „generično zdravilo“.
This means that it contains the same active substance (miglustat) and works in the same way as a ‘reference medicine' already authorised in the European Union (EU) called Zavesca.
To pomeni, da vsebuje enako zdravilno učinkovino in ima enak način delovanja kot referenčno zdravilo Zavesca, ki je že odobreno v Evropski uniji (EU).
Studies on the benefits and risks of the active substance in the approved use have already been carried out with the reference medicine, Zavesca, and do not need to be repeated for Yargesa.
Študije o koristih in tveganjih zdravilne učinkovine pri dovoljenih uporabah so že bile izvedene z referenčnim zdravilom Zavesca, zato jih ni treba ponoviti za zdravilo Yargesa.
Other information about Yargesa
Druge informacije o zdravilu Yargesa
Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Yargesa have been included in the summary of product characteristics and the package leaflet.
Priporočila in varnostni ukrepi, ki jih morajo za varno in učinkovito uporabo zdravila Yargesa upoštevati zdravstveni delavci in bolniki, so vključeni v povzetek glavnih značilnosti zdravila in navodilo za njegovo uporabo.
For more information about treatment with Yargesa, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Za več informacij o zdravljenju z zdravilom Yargesa preberite navodilo za uporabo (ki je tudi del EPAR) ali se posvetujte z zdravnikom ali farmacevtom.
What are the benefits and risks of Yargesa?
Kakšne so koristi in tveganja, povezani z zdravilom Yargesa?
What is Yargesa and what is it used for?
Kaj je zdravilo Yargesa in za kaj se uporablja?
A lower dose should be used in patients with reduced kidney function and those who develop diarrhoea.
Pri bolnikih z zmanjšanim delovanjem ledvic in tistih, pri katerih se pojavi driska, je treba uporabiti nižji odmerek.
Yargesa is available as 100 mg capsules to be taken by mouth.
Zdravilo Yargesa je na voljo v obliki 100-miligramskih kapsul, ki se jemljejo peroralno.
It is not intended to provide practical advice on how to use Yargesa.
Povzetek ni namenjen zagotavljanju praktičnih nasvetov o njegovi uporabi.
Patients with this disease lack an enzyme that breaks down a type of fat called glucosylceramide.
Bolnikom s to boleznijo primanjkuje encim, ki razgrajuje vrsto maščobe, imenovane glukozilceramid.
By preventing the enzyme from working, miglustat can reduce the production of glucosylceramide in cells, thereby reducing the symptoms of type-1 Gaucher disease.
Miglustat lahko s preprečevanjem delovanja encima zmanjša tvorbo glukozilceramida v celicah in s tem zmanjša simptome Gaucherjeve bolezni tipa 1.
Yargesa is a medicine used to treat adults with mild to moderate type-1 Gaucher disease.
Zdravilo Yargesa se uporablja za zdravljenje odraslih z blago do zmerno obliko Gaucherjeve bolezni tipa 1.
For practical information about using Yargesa, patients should read the package leaflet or contact their doctor or pharmacist.
Za praktične informacije o uporabi zdravila Yargesa naj bolniki preberejo navodilo za uporabo ali se posvetujejo z zdravnikom ali farmacevtom.
Therefore, the CHMP's view was that, as for Zavesca, the benefit outweighs the identified risk.
Zato je odbor CHMP menil, da njegove koristi enako kot pri zdravilu Zavesca odtehtajo znana tveganja.
Why is Yargesa approved?
Zakaj je bilo zdravilo Yargesa odobreno?
The medicine can only be obtained with a prescription and treatment should be supervised by doctors who are experienced in the management of Gaucher disease.
Predpisovanje in izdaja zdravila Yargesa je le na recept, zdravljenje z njim pa mora uvesti zdravnik specialist, ki ima izkušnje z zdravljenjem Gaucherjeve bolezni.
The active substance in Yargesa, miglustat, prevents an enzyme called glucosylceramide synthase from working.
Zdravilna učinkovina zdravila Yargesa, miglustat, preprečuje delovanje encima, imenovanega glukozilceramid sintaza.
How does Yargesa work?
Kako zdravilo Yargesa deluje?
How is Yargesa used?
Kako se zdravilo Yargesa uporablja?
How has Yargesa been studied?
Kako je bilo zdravilo Yargesa raziskano?
EU number Invented name Strength Pharmaceutical form Route of administration Packaging Content (concentration) Package size EU/1/02/235/001 Monotard
Vsebnost (koncentracija)
Tavanic is marketed in the following EU Member States: Austria, Belgium, Bulgaria, Cyprus, Czech Republic, Estonia, Finland, France, Germany, Greece, Hungary, Ireland, Italy, Lithuania, Luxembourg, Malta, the Netherlands, Poland, Portugal, Slovakia, Slovenia, Spain, Sweden and United Kingdom.
Zdravilo Tavanic se trži v naslednjih državah članicah EU: Avstriji, Belgiji, Bolgariji, Cipru, Češki republiki, Estoniji, Finski, Franciji, Nemčiji, Grčiji, Madžarski, Irski, Italiji, Litvi, Luksemburgu, Malti, Nizozemski, Poljski, Portugalski, Slovaški, Sloveniji, Španiji, Švedski in Združenem Kraljestvu.
The European Commission issued a decision on 31 July 2012.
Evropska komisija je odločbo izdala dne 31. julija 2012.
Tavanic is authorised in the EU via national procedures.
Zdravilo Tavanic so odobrili v EU z nacionalnimi postopki.
Why was Tavanic reviewed?
Zakaj je bilo zdravilo Tavanic pregledano?
Tavanic is an antibiotic that belongs to the group ‘fluoroquinolones'.
Zdravilo Tavanic je antibiotik, ki spada v skupino „fluorokinolonov“.
After reviewing the available data supporting the use of the medicine, the CHMP agreed that:
Po pregledu razpoložljivih podatkov, ki podpirajo uporabo zdravila, je odbor CHMP potrdil, da:
On 24 May 2012 the European Medicines Agency completed a review of Tavanic.
Evropska agencija za zdravila je 24. maja 2012 končala pregled zdravila Tavanic.
The company that markets these medicines is Sanofi.
Ta zdravila trži družba Sanofi.
It works by blocking an enzyme that bacteria use to make copies of their DNA.
Deluje tako, da zavira encim, ki ga bakterije uporabljajo za kopiranje svoje DNK.
On 11 October 2010, the European Commission referred the matter to the CHMP in order to harmonise the marketing authorisations for Tavanic in the EU.
Evropska komisija je 11. oktobra 2010 zadevo napotila k odboru CHMP z namenom uskladitve dovoljenj za promet z zdravilom Tavanic v EU.
This has led to divergences across Member States in the way the medicine can be used, as seen in the differences in the summaries of product characteristics (SmPCs), labelling and package leaflets in the countries where the medicine is marketed.
To je povzročilo razlike med državami članicami glede tega, kako se zdravilo lahko uporablja, kar se izraža v razlikah med povzetki glavnih značilnosti zdravila, označevanji in navodili za uporabo v državah, v katerih se zdravilo trži.
The Agency's Committee for Medicinal Products for Human Use (CHMP) concluded that there is a need to harmonise the product information for Tavanic in the European Union (EU).
Odbor za zdravila za uporabo v humani medicini (CHMP) je zaključil, da je treba uskladiti informacije o zdravilu Tavanic v Evropski uniji (EU).
The amended information to doctors and patients is available here for solution for infusion and tablets.
Spremenjene informacije za zdravnike in bolnike so na voljo na povezavah raztopina za infundiranje in tablete.
The CHMP also harmonised other sections of the SmPC including the addition of a new warning in section 4.4 recommending that an eye specialist should be consulted if vision becomes impaired or any effects on the eyes are experienced.
Odbor CHMP je uskladil tudi druga poglavja povzetka glavnih značilnosti zdravila, vključno z dodatkom novega opozorila v poglavju 4.4, ki priporoča, da se je treba posvetovati z okulistom, če pride do poslabšanja vida ali kakršnih koli učinkov na oči.
Tavanic is currently used to treat various infections and is available as tablets or solution for infusion.
Zdravilo Tavanic se trenutno uporablja za zdravljenje različnih okužb in je na voljo v obliki tablet ali raztopine za infundiranje.
In addition, the Committee added new side effects in section 4.8 including ligament rupture, hypoglycaemic coma, benign intracranial hypertension, as well as palpitations and ventricular tachycardia, which may result in cardiac arrest.
Poleg tega je poglavju 4.8 dodal nove neželene učinke, vključno z rupturo ligamenta, hipoglikemično komo, benigno intrakranialno hipertenzijo ter palpitacijami in ventrikularno tahikardijo, ki lahko povzročita srčni zastoj.
Based on the data reviewed, the CHMP decided a harmonisation of the contraindications of Tavanic in patients hypersensitive (allergic) to levofloxacin, any other quinolone or any of the excipients, in patients with epilepsy, in patients with history of tendon disorders related to fluoroquinolone administration, in children or growing adolescents, during pregnancy and in breast-feeding women.
Na podlagi pregledanih podatkov se je odbor CHMP odločil za uskladitev kontraindikacij pri zdravilu Tavanic pri bolnikih s preobčutljivostjo za (alergijo na)levofloksacin, katere koli druge kinolone ali katero koli pomožno snov, pri bolnikih z epilepsijo, bolnikih z anamnezo težav s kitami, povezanih z uporabo fluorokinolona, pri otrocih ali mladostnikih, ki še rastejo, med nosečnostjo in pri doječih materah.
The CHMP, in the light of the data submitted and the scientific discussion within the Committee, was of the opinion that the SmPCs, labelling and package leaflets should be harmonised across the EU.
Odbor CHMP je ob upoštevanju predloženih podatkov in interne znanstvene razprave odločil, da je treba uskladiti povzetke glavnih značilnosti zdravila, označevanje in navodila za uporabo v vsej EU.
By doing this, it stops the bacteria that are causing an infection from growing and multiplying.
Tako ustavi rast in razmnoževanje bakterij, ki povzročajo okužbo.
Having harmonised the indications, the CHMP also harmonised the recommendations on the posology and frequency of administration of Tavanic, including the posology for acute exacerbations of chronic bronchitis and pyelonephritis.
Ker je odbor CHMP uskladil indikacije, je uskladil tudi priporočila za odmerjanje in pogostnost uporabe zdravila Tavanic, vključno z odmerjanjem pri akutnih eksacerbacijah kroničnega bronhitisa in pri pielonefritisu.
What is Tavanic?
Kaj je zdravilo Tavanic?
• Tavanic 250 mg and 500 mg film-coated tablets are indicated in acute bacterial sinusitis, acute exacerbation of chronic bronchitis, community-acquired pneumonia and complicated skin and soft tissue infections only when other commonly used antibacterial agents are not recommended.
• je zdravilo Tavanic 250 mg in 500 mg filmsko obložene tablete indicirano za akutni bakterijski sinuzitis, akutno eksacerbacijo kroničnega bronhitisa, pljučnico, pridobljeno v skupnosti, ter komplicirane okužbe kože in mehkega tkiva samo, če drugi pogosto uporabljani antibiotiki niso priporočljivi.
• Tavanic 5mg/ml solution for infusion is indicated in community-acquired pneumonia and complicated skin and soft tissue infections only when other commonly used antibacterials are not recommended.
• je zdravilo Tavanic 5 mg/ml raztopina za infundiranje indicirano za pljučnico, pridobljeno v skupnosti, ter komplicirane okužbe kože in mehkega tkiva samo, če drugi pogosto uporabljani antibiotiki niso priporočljivi.
They are also indicated in pyelonephritis and complicated urinary tract infections (UTI), chronic bacterial prostatitis, uncomplicated cystitis and for the post-exposure prophylaxis and curative treatment of
Indicirano je tudi za pielonefritis, komplicirane okužbe sečil, kronični bakterijski prostatitis, nekomplicirani cistitis ter profilakso proti antraksu po izpostavitvi z inhalacijo in kurativno zdravljenje inhalacijskega antraksa;
Tavanic was identified as needing harmonisation by the Co-ordination Group on the Mutual and Decentralised Procedures - Human (CMD(h)).
Usklajevalna skupina za postopek z medsebojnim priznavanjem in decentralizirani postopek - zdravila za uporabo v humani medicini (CMD(h)) je ugotovila, da je za zdravilo Tavanic potrebna uskladitev.
chronic bacterial prostatitis, and for the post-exposure prophylaxis and curative treatment of
Indicirano je tudi za pielonefritis, komplicirane okužbe sečil, kronični bakterijski prostatitis ter profilakso proti antraksu po izpostavitvi z inhalacijo in kurativno zdravljenje inhalacijskega antraksa.
This cycle of treatment is repeated every two weeks, until the disease gets worse or the patient cannot tolerate the treatment.
Tak cikel zdravljenja se ponavlja vsaka dva tedna, dokler se bolezen ne poslabša ali bolnik ne more prenašati zdravljenja.
The European Commission granted a marketing authorisation valid throughout the European Union for Zaltrap on 1 February 2013.
Evropska komisija je dovoljenje za promet z zdravilom Zaltrap, veljavno po vsej Evropski uniji, izdala 1. februarja 2013.
What measures are being taken to ensure the safe and effective use of Zaltrap?
Kateri ukrepi se izvajajo za zagotovitev varne in učinkovite uporabe zdravila Zaltrap?
The main measure of effectiveness was the average length of time that patients survived after treatment.
Glavno merilo učinkovitosti je bilo povprečno preživetje bolnikov po zdravljenju.
What is Zaltrap and what is it used for?
Kaj je zdravilo Zaltrap in za kaj se uporablja?
The full EPAR for Zaltrap can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Celotno evropsko javno poročilo o oceni zdravila (EPAR) za zdravilo Zaltrap je na voljo na spletni strani agencije: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Although medicines containing the same active substance are available for injection into the eye, Zaltrap must not be injected into the eye as it was not developed for such use and may cause local damage.
Čeprav so zdravila z enako zdravilno učinkovino na voljo za injiciranje v oko, se zdravila Zaltrap ne sme injicirati v oko, ker ni bilo razvito za tako uporabo in lahko povzroči lokalne poškodbe.
What benefits of Zaltrap have been shown in studies?
Kakšne koristi je zdravilo Zaltrap izkazalo v študijah?
Other information about Zaltrap
Druge informacije o zdravilu Zaltrap
This is a summary of the European public assessment report (EPAR) for Zaltrap.
To je povzetek evropskega javnega poročila o oceni zdravila (EPAR) za zdravilo Zaltrap.
It is not intended to provide practical advice on how to use Zaltrap.
Povzetek ni namenjen zagotavljanju praktičnih nasvetov o njegovi uporabi.
What are the risks associated with Zaltrap?
Kakšna tveganja so povezana z zdravilom Zaltrap?
Although Zaltrap is associated with significant side effects, which can be severe enough to force treatment to be stopped, the results of the large main study show that there is a small but clinically significant benefit in prolonging the life of treated patients in whom previous treatment failed.
Čeprav je zdravilo Zaltrap povezano s pomembnimi neželenimi učinki, ki so lahko dovolj resni, da zahtevajo ukinitev zdravljenja, rezultati velike glavne študije kažejo, da obstaja majhna, a klinično pomembna korist pri podaljševanju preživetja zdravljenih bolnikov, pri katerih je bilo predhodno zdravljenje neuspešno.
Zaltrap is given as an infusion (drip) into the vein over one hour, at a dose of 4 mg per kilogram body weight.
Zdravilo Zaltrap se daje z infundiranjem (kapalno infuzijo) v veno v obdobju ene ure in v odmerku 4 mg na kilogram telesne mase.
Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Zaltrap have been included in the summary of product characteristics and the package leaflet.
Priporočila in varnostni ukrepi, ki jih morajo za varno in učinkovito uporabo zdravila Zaltrap upoštevati zdravstveni delavci in bolniki, so vključeni v povzetek glavnih značilnosti zdravila in navodilo za njegovo uporabo.
Zaltrap was investigated in one main study involving 1,226 adults with metastatic colorectal cancer that had not responded to oxaliplatin-based treatment.
Zdravilo Zaltrap so raziskovali v eni glavni študiji, ki je vključevala 1 226 odraslih z metastatskim kolorektalnim rakom, ki se ni odzval na zdravljenje na osnovi oksaliplatina.
Why is Zaltrap approved?
Zakaj je bilo zdravilo Zaltrap odobreno?
Overall, the European Medicines Agency decided that Zaltrap's benefits are greater than its risks and recommended that it be approved for use in the EU.
Evropska agencija za zdravila je zato zaključila, da so koristi zdravila Zaltrap večje od z njim povezanih tveganj, in priporočila, da se odobri za uporabo v EU.
In this study, Zaltrap was more effective than placebo at increasing survival of patients: patients treated with Zaltrap plus FOLFIRI lived an average of 13.5 months, whereas patients treated with placebo and FOLFIRI lived an average of 12.1 months.
V tej študiji je bilo zdravilo Zaltrap učinkovitejše od placeba pri podaljševanju preživetja bolnikov: bolniki, zdravljeni z zdravilom Zaltrap in shemo FOLFIRI, so živeli povprečno 13,5 meseca, bolniki, zdravljeni s placebom in shemo FOLFIRI, pa 12,1 meseca.
As a result, the cancer cells cannot develop their own blood supply and are starved of oxygen and nutrients, so helping to slow down the growth of tumours.
Zaradi tega se rakave celice ne morejo več oskrbovati s krvjo ter dobivajo premalo kisika in hranil, kar pripomore k upočasnjeni rasti tumorjev.
The medicine contains the active substance aflibercept.
Zdravilo vsebuje zdravilno učinkovino aflibercept.
Zaltrap is a cancer medicine used to treat adults with metastatic colorectal cancer (cancer of the large bowel that has spread to other parts of the body) for whom treatment based on another medicine, oxaliplatin, has not worked or the cancer got worse.
Zaltrap je zdravilo proti raku, ki se uporablja za zdravljenje odraslih z metastatskim kolorektalnim rakom (rakom debelega črevesa, ki se je razširil na druge dele telesa), pri katerih zdravljenje na osnovi drugega zdravila, oksaliplatina, ni delovalo ali pa se je rak poslabšal.
For more information about treatment with Zaltrap, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Za več informacij o zdravljenju z zdravilom Zaltrap preberite navodilo za uporabo (ki je prav tako del EPAR) ali se posvetujte z zdravnikom ali farmacevtom.
By binding to VEGF and PlGF, aflibercept stops them having an effect.
Z vezavo na VEGF in PIGF jima aflibercept prepreči učinkovanje.
Zaltrap is used with FOLFIRI, which is a treatment combining the medicines irinotecan, 5-fluorouracil, and folinic acid.
Zdravilo Zaltrap se uporablja skupaj s shemo FOLFIRI, tj. zdravljenjem, ki vključuje zdravila irinotekan, 5-fluorouracil in folno kislino.
Zaltrap can only be obtained with a prescription and treatment should be supervised by a doctor who is experienced in using cancer medicines.
Predpisovanje in izdaja zdravila Zaltrap je le na recept, zdravljenje z njim pa mora nadzorovati zdravnik, ki ima izkušnje z uporabo zdravil za zdravljenje raka.
For practical information about using Zaltrap, patients should read the package leaflet or contact their doctor or pharmacist.
Za praktične informacije o uporabi zdravila Zaltrap naj bolniki preberejo navodilo za uporabo ali se posvetujejo z zdravnikom ali farmacevtom.
This is then followed by the FOLFIRI treatment.
Temu sledi zdravljenje po shemi FOLFIRI.
The most common side effects with Zaltrap in combination with FOLFIRI (which may affect more than 20 patients in 100) are leucopenia and neutropenia (low levels of white cells in the blood, including the type that fight infections), diarrhoea, proteinuria (protein in the urine), increased blood levels of liver enzymes (aspartate and alanine transaminases), stomatitis (inflammation of the mouth), tiredness, thrombocytopenia (low blood platelet counts), hypertension (high blood pressure), weight loss, decreased appetite, epistaxis (nose bleeds), abdominal pain, dysphonia (speech disturbance), increases in creatinine in the blood (a marker of kidney problems), and headache.
Najpogostejši neželeni učinki zdravila Zaltrap v kombinaciji s shemo FOLFIRI (ki se lahko pojavijo pri več kot 20 bolnikih od 100) so levkopenija in nevtropenija (nizko število belih krvnih celic v krvi, vključno s tistimi, ki se borijo proti okužbam), driska, proteinurija (beljakovine v urinu), zvišane ravni jetrnih encimov (aspartat- in alanin-transaminaz) v krvi, stomatitis (vnetje ustne sluznice), utrujenost, trombocitopenija (nizko število krvnih ploščic), hipertenzija (visok krvni tlak), izguba telesne mase, zmanjšan apetit, epistaksa (krvavitev iz nosu), bolečine v trebuhu, disfonija (motnja govora), zvišan kreatinin v krvi (označevalec delovanja ledvic) in glavobol.
How is Zaltrap used?
Kako se zdravilo Zaltrap uporablja?
The active substance in Zaltrap, aflibercept, is a protein that attaches to vascular endothelial growth factor (VEGF) and placenta growth factor (PlGF), substances that circulate in the blood and make blood vessels grow.
Zdravilna učinkovina v zdravilu Zaltrap, aflibercept, je beljakovina, ki se veže na žilni endotelijski rastni faktor (VEGF) in placentni rastni faktor (PIGF), tj. snovi, ki krožita po krvi in omogočata rast žil.
The most common effects that led to treatment being permanently stopped were problems with the circulation including hypertension, infections, tiredness, diarrhoea, dehydration, stomatitis, neutropenia, proteinuria, and pulmonary embolism (a clot in a blood vessel supplying the lungs).
Najpogostejši neželeni učinki, ki so privedli do trajne ukinitve zdravljenja, so bili težave z obtokom, vključno s hipertenzijo, okužbe, utrujenost, driska, dehidracija, stomatitis, nevtropenija, proteinurija in pljučna embolija (strdek v žili, ki oskrbuje pljuča).
Zaltrap was compared with placebo (a dummy treatment) when added to FOLFIRI.
Zdravilo Zaltrap so primerjali s placebom (zdravilom brez zdravilne učinkovine) ob dodajanju zdravljenju po shemi FOLFIRI.
For the full list of all side effects reported with Zaltrap, see the package leaflet.
Za celoten seznam neželenih učinkov, o katerih so poročali pri uporabi zdravila Zaltrap, glejte navodilo za uporabo.
For further details, see the package leaflet.
Za več informacij glejte navodilo za uporabo.
Treatment should be discontinued, delayed, or the dose may have to be adjusted, in patients who develop certain side effects.
Pri bolnikih, pri katerih se pojavijo določeni neželeni učinki, je treba zdravljenje prekiniti, odložiti ali zmanjšati odmerek.
How does Zaltrap work?
Kako zdravilo Zaltrap deluje?
1000 mg Granules for oral suspension Oral use
1000mg Zrnca za peroralno raztopinoPeroralna uporaba vrečka (alu)
(Invented) nameStrength Pharmaceutical Form Route of AdministrationImmediate PackagingPack size
Farmacevtska oblika Pot uporabe
The European Commission issued a decision on this opinion on 21 January 2013.
Evropska komisija je izdala sklep o tem mnenju 21. januarja 2013.
Questions and answers on the review of tolperisonecontaining medicines
Vprašanja in odgovori v zvezi s pregledom zdravil, ki vsebujejo tolperizon
The full changes made to the information to doctors and patients are detailed here.
Vse spremembe informacij za zdravnike in bolnike so na voljo tukaj.